ASTRO Booth Number 2449-- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that its Xoft subsidiary will be showcasing its Xoft ® Axxent ® Electronic Brachytherapy System ® at the American Society for Radiation Oncology’s (ASTRO) 55 th Annual Meeting being held from September 22-25, 2013 in Atlanta at booth #2449. The Xoft System can be used to treat non-melanoma skin cancer (NMSC), early-stage breast cancer with Intraoperative Radiation Therapy (IORT) and Accelerated Partial Breast Irradiation (APBI), vaginal, endometrial and cervical cancer.
“This year’s activities at ASTRO demonstrate iCAD’s commitment to delivering targeted, innovative and cost-effective radiation therapy solutions to radiation oncologists to help them to more effectively treat a variety of cancers,” said Ken Ferry, President and CEO of iCAD. “It’s an exciting time for iCAD with new product introductions, significant progress in our post-market breast cancer study, and the presentation of longer term clinical data that supports the increased momentum of our NMSC application.”
The Company’s technology will be featured in the following educational sessions and at the Company’s booth:
|Topic:||“Electronic Brachytherapy Utilizing the Xoft ® System for the Treatment of Non-Melanoma Skin Cancer”|
|Presentation:||Monday, September 23 from 10:15 to 10:45 a.m.|
|Presenter:||Ajay Bhatnagar, MD, MBA, Cancer Treatment Services Arizona, Affiliate of 21 st Century Oncology, Adjunct Assistant Professor of Radiation Oncology, University of Pittsburgh School of Medicine and DermEbx|
|Location:||Rear of 100 Aisle, Exhibit Hall B1|
New Data on the Use of the Xoft System for Non-Melanoma Skin Cancer (NMSC)
|Topic:||“Electronic Brachytherapy for the Treatment of Non-Melanoma Skin Cancer: Results at Three Years,” which presents new clinical data assessing adverse effects, cosmesis and recurrence rates related to high dose rate (HDR) electronic brachytherapy for the treatment of NMSC with the Xoft System.|
|Presentation:||Tuesday, September 24 at 2:10 p.m.|
Scientific Session S in Room B405
Breast IORT Post-market Study Update
|Topic:||“A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) using the Xoft Axxent eBx System at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer,” providing discussion of the ongoing study, which has 19 participating centers and more than 150 patients treated and which continues to enroll patients and enlist centers.|
|Presentation:||Throughout Exhibit Hall hours|
|Location:||iCAD Exhibit Booth 2449|
About ASTRORadiation oncologists, medical physicists, dosimetrists, radiation therapists, radiation oncology nurses and nurse practitioners, biologists, physician assistants and practice administrators comprise ASTRO’s nearly 10,000 members, making it the largest radiation oncology organization of its kind. These medical professionals, found at hospitals, cancer treatment centers and academic research facilities around the globe, make up the radiation therapy treatment teams that are critical in the fight against cancer. Together, these teams, treat more than 1 million cancer patients each year.